The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: So Sibaji, I would have this question on the CDMO business. So if I want to take out the CDMO business revenue -- biologic CDMO business revenue
for this quarter, what would have been the growth for the rest of the business in the constant currency terms?
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: Okay. Okay. I'm just combining two more questions and that is related to the biologics. So I just want to know on the current biotech funding
environment, which we are reading that there is some challenges in the small biotech funding. So do you see there was any impact on the CRO
business services this quarter?
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: And the second question will be now that we have acquired one large facility, so how easy or difficult is it for you, to hire right set of people to fill
in this facility? Or in fact, you are also doing another center at Hyderabad. So how do you ensure that you get right kind of people to fill in those
facilities?
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: Okay. Okay. But the question that would be -- a follow-up on that would be, if there will be any impact of the current funding challenges on your
business going in the rest of the quarters of the year?
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: Right. And...
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JULY 27, 2023 / 8:30AM, SYNN.NS - Q1 2024 Syngene International Ltd Earnings Call
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: No, I think it may stop for a while and it will come back just as we have been during the pandemic time.
Question: Shrikant Akolkar - Asian Markets Securities Private Limited, Research Division - Analyst
: Right, right. And the other question I asked was about the hiring the right set of people in your biologics manufacturing and the new R&D center
at Hyderabad?
| 
